Literature DB >> 1292959

Hemicrania continua and chronic paroxysmal hemicrania: a comparison of pupillometric findings.

F Antonaci1, T Sand, O Sjaastad.   

Abstract

Pupillometric studies were carried out in 9 patients with chronic paroxysmal hemicrania (CPH), in 10 patients with hemicrania continua (HC) and in age- and sex-matched controls (n = 12-17). Studies were carried out in the basal condition and after instillation of 2% tyramine, 1% OH-amphetamine, or 1% phenylephrine. The pupillary response to tyramine in HC was more marked than in controls on a percentage increase basis, but not so much when the increment is calculated in absolute values. In this series, there was no asymmetrical response (relative miosis on the symptomatic side) like in previous case reports. The pupil reaction was less in HC than in CPH after hydroxyamphetamine instillation and without any marked asymmetry. There was no definite evidence of supersensitivity to a directly acting sympathicomimetic agent, phenylephrine. No gross abnormalities as regard the sympathetic function in HC was thus observed. The asymmetry on tyramine testing differed in CPH and HC (most marked in HC). No major emphasis should probably be attached to this finding, since on testing with OH-amphetamine, a similar substance, this finding was not reproduced.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1292959

Source DB:  PubMed          Journal:  Funct Neurol        ISSN: 0393-5264


  3 in total

Review 1.  Hemicrania continua: recent treatment strategies and diagnostic evaluation.

Authors:  Mario F P Peres
Journal:  Curr Neurol Neurosci Rep       Date:  2002-03       Impact factor: 5.081

2.  Chronic daily headaches.

Authors:  Fayyaz Ahmed; Rajsrinivas Parthasarathy; Modar Khalil
Journal:  Ann Indian Acad Neurol       Date:  2012-08       Impact factor: 1.383

Review 3.  Update on hemicrania continua.

Authors:  Elisabetta Cittadini; Peter J Goadsby
Journal:  Curr Pain Headache Rep       Date:  2011-02
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.